Skip to main content

Table 1 Patient’s demographics and clinical characteristics at baselinea as a function of azithromycin treatment response

From: Azithromycin and the microbiota of cystic fibrosis sputum

  Relative
Responder (n = 17) Non-Responder (n = 21) P-value
Demographicsb
 Sex (Male:Female) 7:10 7:14 0.739
 Age (years) 26.06 (21.9–29.9) 25.2 (20.7–30.4) 0.964
 ∆F508 / ∆F508 9 (52.9) 10 (47.6) 1
 FEV1% predicted 44 (32–62) 56 (40–78) 0.270
 FVC % predicted 71 (64–87) 87 (67–99) 0.171
 Body mass index (kg/m2) 20.1 (18.8–21.4) 20.6 (18.9–22.1) 0.402
CF related diseasesb
 Pancreatic sufficiency 2 (11.7) 3 (14.2) 1
 CF-related diabetes 4 (23.5) 1 (4.7) 0.152
 CF-liver disease 4 (23.5) 2 (9.5) 0.378
 Osteopenia/Osteoporosis 5 (29.4) 10 (47.6) 0.326
Cultured pathogenb
Pseudomonas aeruginosa 13 (76.4) 15 (71.4) 1
Staphylococcus aureus 6 (35.2) 7 (33.3) 1
Haemophilus influenzae 1 (5.8) 1 (4.7) 1
Stenotrophomonas maltophilia 2 (11.7) 1 (4.7) 0.576
Escherichia coli 1 (5.8) 1 (4.7) 1
Therapiesb
 Inhaled DNase 12 (70.5) 12 (57.1) 0.506
 Inhaled colistin 0 (0) 1 (4.7) 1
 Inhaled tobramycin 6 (35.2) 7 (33.3) 1
 Inhaled hypertonic saline 5 (29.4) 9 (42.8) 0.506
 Proton pump inhibitor 4 (23.5) 9 (42.8) 0.307
 Inhaled corticosteroids 15 (88.2) 9 (42.8) 0.006
 Long-acting bronchodilator 16 (94.1) 17 (80.9) 0.355
 Short-acting bronchodilator 12 (70.5) 15 (71.4) 1
 Pancreatic enzymes 15 (88.2) 18 (85.7) 1
 Ranitidine 4 (23.5) 1 (4.7) 0.152
 CFTR-modulator 0 (0) 0 (0)
  1. Fisher exact probability test at a two-tailed or Wilcoxon rank-sum (Mann-Whitney) tests were performed
  2. CFTR Cystic fibrosis transmembrane conductance regulator
  3. aVariables were taken from the closest or same day from the Day 0 of azithromycin treatment and patients were categorized as Responder or Non-Responder based on the primary outcome definition
  4. bData are presented as n (%) or median (inter-quartile range)